You can buy or sell MNPR and other stocks, options, ETFs, and crypto commission-free!
Monopar Therapeutics Inc. Common Stock, also called Monopar Therapeutics, is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Read More Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
52 Week High
52 Week Low
— per share
Expected Aug 6, Pre-Market